Updates

BIG PHARMA EARNINGS WATCH: GLAXOSMITHKLINE

Oct 29, 2020

Brand Name Big Pharma Giant Surpasses Expectations After Hiking Prices A new Read More

BIG PHARMA EARNINGS WATCH: MERCK, NOVARTIS & PFIZER

Oct 28, 2020

Brand Name Drug Companies Beat Wall Street Expectations After Repeatedly Read More

ICYMI: BIG PHARMA’S PANDEMIC PRICE HIKES AND PATENT ABUSE UNDERSCORE URGENCY FOR ACTION

Oct 28, 2020

Big Pharma’s Pandemic Price Hikes and Patent Abuse Underscore Urgency for Read More

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Oct 13, 2020

Price Hikes Fuel Q3 Earnings Beat For Brand Name Giant As millions of Read More

CSRXP: PRESIDENTIAL CAMPAIGNS MUST BACK BIPARTISAN, MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE

Oct 13, 2020

Surrogates for the 2020 Candidates Should Demonstrate Commitment To Lowering Read More

SECOND OPINION: PHARMA-BACKED REBATE RULE WOULD INCREASE OOP COSTS AND PREMIUMS FOR SENIORS — DO NOTHING TO LOWER RX PRICES

Oct 5, 2020

Big Pharma Claims Misguided Proposal Would Benefit Patients, Facts Show It Read More

CSRXP: ASTRAZENECA LEADS BIG PHARMA IN BRAZEN ASSAULT ON CRITICAL 340B PROGRAM, MUST BE HELD ACCOUNTABLE

Oct 1, 2020

Brand Name Drug Company Shirks Requirement to Provide Affordable Medications Read More

CSRXP COMMENDS LAWMAKERS FOR REFOCUSING CRITICAL ATTENTION ON BIG PHARMA’S EGREGIOUS PRICE HIKES AND PRACTICES

Sep 30, 2020

House Committee on Oversight and Reform to Question Big Pharma Executives Read More

DOSE OF REALITY: LAWMAKERS RIGHT TO TRAIN RENEWED FOCUS ON BIG PHARMA’S PRICE-GOUGING AND ANTI-COMPETITIVE TACTICS

Sep 29, 2020

Brand Name Drug Companies Must be Held Accountable for Pandemic Price Hikes Read More

NEW STUDY: BIG PHARMA’S BIOLOGIC PATENT ABUSE WILL COST AMERICAN PATIENTS AN ADDITIONAL $25 BILLION WITHOUT REFORM

Sep 22, 2020

Report Finds Market-Based Solutions to Boost Biosimilar Competition and Hold Read More